MiXeno™ - a Rapid and Simple Strategy for Model Humanization

Despite the unprecedented success of immune checkpoint antibodies for a variety of cancer types, a lack of immunocompetent preclinical mouse models remains a major challenge for the development of novel immunotherapeutics.